MannKind News and Activities

MannKind is one of the...

• Russell 3000;
• TOB Iconic 10,000.

MannKind is a company listed under the stock ticker MNKD (US).

Acquisition, funding and merger involving MannKind.

• MannKind has announced the acquisition of scPharmaceuticals  (posted on August 28 2025).

View the org chart displaying its 45 main executives

Most searched biographies at MannKind

• Michael Castagna, Chief Executive Officer and Director
• Michael Friedman, Director
• Tony Hooper, Director

Popular executive movements at MannKind

• Tara Hendrzak has joined the company as Vice President of Marketing  (posted on January 28 2026).

Create your alert
to follow the executive moves at MannKind.

MannKind has 1,918 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).
• Novartis has announced the acquisition of Myricx Bio  (posted on July 6 2026).
• Ipsen has announced the acquisition of Kartos Therapeutics  (posted on July 3 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by MannKind

• MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D | MannKind Corporation
• MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF | MannKind Corporation
• Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems | MannKind Corporation
• MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases | MannKind Corporation
• MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | MannKind Corporation
• MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 | MannKind Corporation
• MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 | MannKind Corporation
• MannKind to Participate in Upcoming Investor Conferences | MannKind Corporation
• MannKind Announces Settlement of Convertible Senior Notes | MannKind Corporation
• MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | MannKind Corporation
• View more press releases Close

Social media about MannKind

• MannKind on Wikipedia, Google News & Yahoo Finance
• MannKind on LinkedIn, X (Twitter) & YouTube